key: cord-0951355-xxymb9mz
authors: Ngere, Isaac; Dawa, Jeanette; Hunsperger, Elizabeth; Otieno, Nancy; Masika, Moses; Amoth, Patrick; Makayotto, Lyndah; Nasimiyu, Carolyne; Gunn, Bronwyn M.; Nyawanda, Bryan; Oluga, Ouma; Ngunu, Carolyne; Mirieri, Harriet; Gachohi, John; Marwanga, Doris; Munywoki, Patrick K.; Odhiambo, Dennis; Alando, Moshe D.; Breiman, Robert F.; Anzala, Omu; Njenga, M. Kariuki; Bulterys, Marc; Herman-Roloff, Amy; Osoro, Eric
title: sssHigh seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya
date: 2021-09-02
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.08.062
sha: 895b72118fa0e91415ad3b6047cc746c0b9c3b25
doc_id: 951355
cord_uid: xxymb9mz

Background The lower-than-expected COVID-19 morbidity and mortality in Africa has been attributed to multiple factors, including weak surveillance. We estimated the burden of SARS-CoV-2 infections eight months into the epidemic in Nairobi, Kenya. Methods We conducted a population-based cross-sectional survey using multi-stage random sampling to select households within Nairobi in November 2020. Sera from consenting household members were tested for antibodies to SARS-CoV-2. Seroprevalence was estimated after adjusting for population structure and test performance. Infection fatality ratios (IFRs) were calculated by comparing study estimates to reported cases and deaths. Results Among 1,164 individuals, the adjusted seroprevalence was 34.7% (95%CI 31.8-37.6). Half the enrolled households had at least one positive participant. Seropositivity increased in more densely populated areas (spearman's r=0.63; p=0.009). Individuals aged 20-59 years had at least 2-fold higher seropositivity than those aged 0-9 years. The IFR was 40 per 100,000 infections, with individuals ≥60 years old having higher IFRs. Conclusion Over one-third of Nairobi residents had been exposed to SARS-CoV-2 by November 2020, indicating extensive transmission. However, the IFR was >10-fold lower than that reported in Europe and the United States, supporting the perceived lower morbidity and mortality in sub–Saharan Africa.

Sixteen months after emergence of the coronavirus disease of 2019 (COVID- 19) , severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection had been confirmed in almost 140 million people globally and led to >2.9 million deaths (WHO, 2021a). In April 2020, the World Bank expressed concern that high virus transmission posed the greatest risk in densely populated urban areas, especially those with poor infrastructure and service delivery systems (The World Bank, 2020).

In Africa, the urban population stood at 588 million people in 2020, with 50% of this population living in informal settlements, while 70% of the population were self-employed or worked in unregulated sectors, making them vulnerable to income losses and less able to adhere to restrictions and lockdowns (United Nations et al., 2019). These workers use overcrowded public transport systems and marketplaces, which make social distancing almost impossible (Mitlin, 2020;  UNHABITAT, 2020). Yet, despite these challenges, countries within sub-Saharan Africa consistently reported lower COVID-19 cases and deaths throughout the pandemic when compared to other continents. Public health experts advanced many hypotheses to explain this outcome, ranging from poor surveillance, suboptimal testing and underreporting, to younger population, warmer and humid weather, and prior exposure to other cross-reacting coronaviruses (Njenga et 

A WHO unity protocol aligned population-based cross-sectional survey, using multi-stage random sampling of households across the 17 administrative sub-counties within Nairobi City County, was conducted from November 2 to 23, 2020 (WHO, 2020c). Consenting residents, irrespective of age, in selected households, who had lived in the city for at least six months preceding the survey were enrolled. Persons with reported or documented contraindications to venipuncture were excluded.

We assumed a seroprevalence of 5-8%, relative precision of 30%, and a design effect of 1.5 to obtain a sample size of 1,216 participants. Estimating an average of 3 enrolled study participants per household, we planned to enroll 406 households at identified geospatial coordinates (geocodes) but sampled 50% more geocodes to cater for replacements households. Household selection was conducted using multi-stage random sampling. First, half of the wards in each of the 17 sub-counties were randomly selected, and then the number of households allocated to each ward was determined in proportion to its population size in the national census report (Kenya National Bureau of Statistics, 2019a). Subsequently, random geospatial coordinates (geocodes) were generated using QGIS Version 2.18.15 within each ward, corresponding to the number of allocated households (QGIS Development Team, 2009). Uninhabited areas such as the central business district, game parks, industrial parks, and restricted government compounds/institutions were excluded before generation of geocodes.

Trained study teams which included a nurse/clinician, a laboratory technologist, and a community health volunteer, used hand-held global positioning system (GPS) devices to locate households closest to the geocodes. If no one was present within the household, a revisit within 72 hours occurred before replacing the household with the next geocode within the ward, from the list of replacement geocodes.

A household geocode was also replaced if the head of household declined participation of the household and there was no other consenting household near the geocode. In households where a consenting adult was present, all eligible individuals were enrolled upon providing written consent (for adults) and parental permission and assent (for minors ≥12 years). Revisits to enroll household members who were not present during the first visit were scheduled within seven days.

Data were collected electronically using tablets on the REDCap© platform. Apart from the number of household residents, we collected individual data on social and demographic characteristics, medical history, presence of chronic disease, and current (time of visit), recent (last 14 days), and past (last 12 months) symptoms of respiratory illness. Respiratory illness was defined as at least two of the following symptoms: cough, running nose, sore throat, shortness of breath, chills, or fever. Chronic disease was defined as self-reported past diagnosis of hypertension, asthma, diabetes, heart disease, stroke, liver disease, kidney disease cancer, or tuberculosis. Venous blood samples were collected from each participant, transported in a cool box to Kenya Medical Research Institute (KEMRI) laboratory in Nairobi, and sera stored at -80 o C before testing.

Detection of total IgM and IgG antibodies was carried out using the Wantai SARS-CoV-2 two-step antigen sandwich enzyme immunoassay (EIA) kit that uses polystyrene microwell strips coated with 

To validate the Wantai enzyme immunoassay test kit, we investigated whether there was crossreactivity with antibodies to other pathogens commonly detected in patients with acute febrile illness (AFI) in sub-Saharan Africa, including malaria as suggested in other studies (Huibin Lv et al., 2020; Njenga et al., 2020) . This was conducted using blinded sera previously collected from 146 patients as follows:

i. 37 patients with AFI, whose sera were collected before August 2019 (KEMRI protocol approval # 2980).

ii. 20 febrile patients positive for malaria, whose sera was collected before August 2019 (KEMRI protocol approval # 2980).

iii. 89 real-time reverse transcription-polymerase chain reaction (rRT-PCR) confirmed SARS-CoV-2 patients, hospitalized in various health facilities (Kenyatta National Hospital -University of Nairobi research protocol approval #P223/03/2020).

Following a series of optimization runs in our laboratory using true positives and negatives, we determined that 10 washes after addition of sera as opposed to 5 washes as recommended in the manufacturer's instructions were required. This was done to eliminate high background crossreactivity detected with 5 washes.

All sera collected before August 2019 from malaria-positive and negative patients with AFI were negative for SARS-CoV-2 antibodies. In contrast, 79.8% (71/89) of the PCR-confirmed COVID-19 patients tested positive for SARS-CoV-2 antibodies. The sera tested from COVID-19 patients were collected at varying time points after real-time RT-PCR confirmation of SARS-CoV-2 infection, hence the possibility that some of the seronegative patients were sampled during the pre-antibody phase of infection or that the antibodies had waned if sampling was done long after the primary infection. The date of the first known positive COVID-19 test before admission/isolation was available for seven of the 18 patients whose sera tested negative for SARS-CoV-2 antibodies. For these seven patients, sera were collected a median of 6 days (range 3-51 days) after the first recorded real-time RT-PCR confirmation.

The SARS-CoV-2 seroprevalence was determined in three steps. First, we summarised respondent characteristics by antibody positivity using counts and proportions and used median and interquartile ranges (IQR) for continuous variables. Second, we weighted the seroprevalence through poststratification by raking on sex and age group to the population structure of Nairobi. The age groups applied were 0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, and 60 years and above. Finally, the weighted seroprevalence was adjusted for test characteristics as provided by the manufacturer (sensitivity of 94.4% and specificity of 100%) (Wantai Biological, 2020). The point estimates and 95% confidence interval for the unweighted, weighted and test adjusted seroprevalence estimates were reported. Household seroprevalence was defined as the proportion of households with at least one seropositive member.

We compared the adjusted sub-county seroprevalence to its population density (average number of persons per kilometer 2 ) using Spearman's correlation and reported the coefficient values. Mixedeffects multivariable logistic regression, accounting for survey weights and clustering at household level, was conducted to determine the association between seropositivity and sex, age category, and history of respiratory illness. Adjusted odds ratio and 95% confidence intervals were reported and two-sided p-values <0.05 were considered significant. All data cleaning and analyses were done using R statistical software.

Underestimation of infections was defined as the extent to which SARS-CoV-2 infections within the Nairobi population (both symptomatic and asymptomatic) were detected by the Kenya national testing and surveillance system (Gibbons et al., 2014) . Using the adjusted age-specific seroprevalence from our study, we calculated the number of infections in Nairobi as of 23 November 2020 in each age group and provided 95% confidence intervals. This was compared with the cumulative number of positive cases in Nairobi reported by the Kenya Ministry of Health (MoH) by the end of November 2020, to obtain age-specific underestimation levels. Age-specific multiplication factors were expressed as 'n'-fold i.e., the value by which reported cases would be amplified to obtain the true number of infections.

Infection fatality ratio (IFR) was defined as the probability of death following infection. IFR was calculated by dividing the age-specific number of reported COVID-19 deaths (by the end of Administrative approval was provided by the Kenya MoH and Nairobi City County administration.

All participants provided written consent or assent before enrollment. Forty-five percent of those with chronic illness were ≥60 years old, 29.5% were 50-59 years old, and 1.7% were <20 years old. One-third of respondents reported a history of respiratory illness sometime during the year 2020 ( Table 1) .

The crude unweighted seroprevalence was 33 (Figure 2) .

Adjusting for sex, history of respiratory illness, and reported chronic disease, the age groups of [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] years, 20-29 years, 30-39 years, 40-49 years, and 50-59 years had a nearly 2 to 3-fold higher odds of seropositivity compared to the 0-9 years age group (Figure 3) . 

The adjusted seroprevalence of 34.7% indicated that at least 1.5 million Nairobi residents may have been infected with SARS-CoV-2 since March 2020. These findings indicate the national surveillance system detected only 2.4% of all SARS-CoV-2 infections in Nairobi, reflecting an underestimation ratio of 42:1. Older age groups had lower underestimation levels, with a ratio of 17:1 for cases 50-59 years old, and 10:1 for cases ≥60 years old, when compared to a ratio of 101:1 for cases <10 years old.

The estimated overall IFR associated with SARS-CoV-2 infections was 40 deaths per 100,000

infections among Nairobi residents but ranged from 1 death per 100,000 infections among 10-19 years old to 115 deaths per 100,000 infections among those ≥60 years old. Those ≥60 years old had a 28fold higher IFR than the county average (Table 3) .

This population-based seroprevalence study of SARS-CoV-2 is among the first to document overall In conclusion, this study demonstrates extensive SARS-CoV-2 transmission in Nairobi during the first eight months of the pandemic, resulting in more than a third of residents and half of the identified households being exposed to the virus. There was significant underreporting of infections by the national surveillance system and a lower-than-expected mortality rate, attributed in part to the youthful Kenyan population. 

SARS-CoV-2 infection among asymptomatic healthcare workers of the emergency department in a tertiary care facility

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

Estimated SARS-CoV-2 Seroprevalence in the US as of

Serosurveillance and the COVID-19 Epidemic in the US: Undetected, Uncertain, and Out of Control

Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review

High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi

The relatively young and rural population may limit the spread and severity of COVID-19 in Africa: a modelling study

Serological Surveillance of COVID-19 Hospitalized Patients in Réunion Island (France) Revealed that Specific Immunoglobulin G Are Rapidly Vanishing in Severe Cases

Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and metaanalysis

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity

Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods

Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

Estimation of total mortality due to COVID-19. Inst Health Metr Eval 2021

Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya

SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility

SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia

Kenya population and housing census Volume I

Kenya population and housing census Volume III

Longitudinal SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, during the first and second waves

Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review

Evaluation of nine commercial SARS-CoV-2 immunoassays | medRxiv 2020

Household Transmission of SARS-CoV-2

The puzzle of the COVID-19 pandemic in Africa

Govt announces extra measures to prevent spread of coronavirus Nairobi

Dealing with COVID-19 in the towns and cities of the global South

Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey

Covid-19 deaths in Africa: prospective systematic postmortem surveillance study

Challenges in interpreting SARS-CoV-2 serological results in African countries

COVID-19 Special Public Health Surveillance Bulletin Issue

Comparison of six commercially available SARS-CoV-2 antibody assays-Choice of assay depends on intended use

Why is There Low Morbidity and Mortality of COVID-19 in Africa?

Access to primary healthcare services and associated factors in urban slums in Nairobi-Kenya

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study

SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis

Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa

Covid-19 in Africa

Urban and Disaster Risk Management Responses to COVID

Air transport, passengers carried | Data

High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

UNHABITAT. COVID-19 in African Cities-Impacts, Responses and Policies Recommendations 2020

United Nations, Department of Economic and Social Affairs, Population Division

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

Emergency Use Authorization. Wantai SARS-CoV-2 Ab ELISA. ELISA for Total Antibody to SARS-CoV-2 2020

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays

WHO. WHO Coronavirus (COVID-19) Dashboard 2021a

The true death toll of COVID-19: estimating global excess mortality 2021b

Critical preparedness, readiness and response actions for COVID-19 2020a

WHO. Serology in the context of COVID-19 2020b

WHO. Unity Studies: Early Investigation Protocols 2020c

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba

We thank the Kenya Ministry of Health (MOH), Nairobi City County, and Nairobi Metropolitan Services for granting permission and actively participating in public sensitization for the study. We acknowledge the Kenya Medical Research Institute (KEMRI) which provided ethical approval, oversight, and field staff that carried out household visits. We would also like to thank the Washington State University Global Health Kenya research and administration staff that supported